Jan Malcolm Sells 325 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) Director Jan Malcolm sold 325 shares of the company’s stock in a transaction that occurred on Friday, July 10th. The shares were sold at an average price of $550.59, for a total value of $178,941.75. Following the completion of the transaction, the director directly owned 450 shares in the company, valued at approximately $247,765.50. The trade was a 41.94% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

United Therapeutics Trading Down 1.0%

NASDAQ UTHR traded down $5.42 during trading hours on Friday, reaching $547.06. 301,306 shares of the company traded hands, compared to its average volume of 526,796. The company has a 50 day moving average of $556.70 and a two-hundred day moving average of $529.44. The stock has a market capitalization of $23.22 billion, a PE ratio of 20.19, a PEG ratio of 1.80 and a beta of 0.58. United Therapeutics Corporation has a 12 month low of $272.12 and a 12 month high of $609.35.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The firm had revenue of $781.50 million during the quarter, compared to the consensus estimate of $797.40 million. During the same period in the prior year, the firm earned $6.63 earnings per share. The firm’s quarterly revenue was down 1.6% compared to the same quarter last year. On average, equities research analysts anticipate that United Therapeutics Corporation will post 26.63 earnings per share for the current year.

Institutional Investors Weigh In On United Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Torren Management LLC acquired a new position in United Therapeutics during the 4th quarter valued at about $26,000. Activest Wealth Management lifted its stake in shares of United Therapeutics by 1,400.0% in the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 56 shares during the period. WealthCollab LLC boosted its holdings in shares of United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 38 shares in the last quarter. Rakuten Securities Inc. increased its stake in shares of United Therapeutics by 76.7% during the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 46 shares during the period. Finally, Entrust Financial LLC bought a new stake in United Therapeutics during the fourth quarter worth approximately $31,000. 94.08% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages have issued reports on UTHR. Royal Bank Of Canada raised their target price on shares of United Therapeutics from $701.00 to $704.00 and gave the stock an “outperform” rating in a report on Tuesday, July 7th. Morgan Stanley set a $516.00 price objective on United Therapeutics in a research note on Thursday, May 7th. Bank of America lowered their price target on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a research report on Friday. Weiss Ratings reiterated a “buy (b)” rating on shares of United Therapeutics in a research report on Thursday, June 11th. Finally, HC Wainwright boosted their target price on shares of United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a research note on Tuesday, March 31st. Ten research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, United Therapeutics has an average rating of “Moderate Buy” and an average price target of $644.82.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.